RT Journal Article
SR Electronic
T1 Increase in preterm stillbirths and reduction in iatrogenic preterm births for fetal compromise: a multi-centre cohort study of COVID-19 lockdown effects in Melbourne, Australia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.04.21264500
DO 10.1101/2021.10.04.21264500
A1 Lisa Hui
A1 Melvin Barrientos Marzan
A1 Stephanie Potenza
A1 Daniel L. Rolnik
A1 Natasha Pritchard
A1 Joanne M. Said
A1 Kirsten R Palmer
A1 Clare L. Whitehead
A1 Penelope M. Sheehan
A1 Jolyon Ford
A1 Ben W. Mol
A1 Susan P. Walker
YR 2021
UL http://medrxiv.org/content/early/2021/10/05/2021.10.04.21264500.abstract
AB Objectives The COVID-19 pandemic has been associated with a worsening of perinatal outcomes in many settings due to the combined impacts of maternal COVID-19 disease, disruptions to maternity care, and overloaded health systems. In 2020, Melbourne endured a unique natural experiment where strict lockdown conditions were accompanied by very low COVID-19 case numbers and the maintenance of health service capacity. The aim of this study was to compare stillbirth and preterm birth rates in women who were exposed or unexposed to lockdown restrictions during pregnancy.Design Retrospective multi-centre cohort study of perinatal outcomes before and during COVID-19 lockdownSetting Birth outcomes from all 12 public maternity hospitals in metropolitan MelbourneInclusion criteria Singleton births without congenital anomalies from 24 weeks’ gestation. The lockdown-exposed cohort were those women for whom weeks 20- 40 of gestation would have occurred during the lockdown period of 23 March 2020 to 14 March 2021. The control cohort comprised all pregnancies in the corresponding periods one and two years prior to the exposed cohort.Main outcome measures Odds of stillbirth, preterm birth (PTB), birth weight < 3rd centile, and iatrogenic PTB for fetal compromise, adjusting for multiple covariates.Results There were 24,017 births in the exposed and 50,017 births in the control group. There was a significantly higher risk of preterm, but not term, stillbirth in the exposed group compared with the control group (0.26% vs 0.18%, aOR 1.49, 95%CI 1.08 to 2.05, P = 0.015). There was also a significant reduction in preterm birth < 37 weeks (5.93% vs 6.23%, aOR 0.93, 95%CI 0.87 to 0.99, P=0.03), largely mediated by a reduction in iatrogenic PTB for live births (3.01% vs 3.27%, aOR 0.89, 95%CI 0.81 to 0.98, P = 0.015), including iatrogenic PTB for suspected fetal compromise (1.25% vs 1.51%, aOR 0.79, 95%CI 0.69 to 0.91, P= 0.001). There was no significant difference in the spontaneous PTB rate between the exposed and control groups (2.69% vs 2.82%, aOR 0.94, 95%CI 0.86 to 0.1.03, P=0.25).Conclusions Lockdown restrictions in a high-income setting, in the absence of high rates of COVID-19 disease, were associated with a significant increase in preterm stillbirths, and a significant reduction in iatrogenic PTB for suspected fetal compromise.Trial registration This study was registered as an observational study with the Australian and New Zealand Clinical Trials Registry (ACTRN12620000878976).Competing Interest StatementLH has received research funding from Ferring Phamaceuticals outside the scope of this work. BWM is a consultant for Guerbet, and has received research grants from Guerbet and Merck. KRP has received consultancy fees from Janssen. DLR has received fees from Alexion for participation in advisory boards unrelated to this work. All other authors declare no competing interests.Clinical TrialACTRN12620000878976Clinical Protocols https://doi.org/10.1101/2021.07.22.21261008 Funding StatementThis study was funded by the Norman Beischer Medical Research Foundation and the University of Melbourne Department of Obstetrics and Gynaecology. LH and BWM are supported by National Health and Medical Research Council investigator grants (GNT1196010 and GNT11766437). The funding bodies had no role in any aspects of the design or conduct of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was given ethical approval from the Human Research Ethics Committees of Austin Health (Ref. HREC/64722/Austin-2020) and Mercy Health (Ref. 2020-031) and is registered as an observational study with the Australian and New Zealand Clinical Trials Registry (ACTRN12620000878976).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNon-identifiable individual participant data is available on request from the Austin Health Human Research Ethics Committee (ethics{at}austin.org.au) and the Mercy Health Human Research Ethics Committee (ethics{at}mercy.com.au). The study investigators may contribute aggregate and non-identifiable individual patient data to national and international collaborations whose proposed use of the data has been ethically reviewed and approved by an independent committee and following signing of an appropriate research collaboration agreement with the University of Melbourne.